Campral 333mg Tablets

Acamprosate calcium is available on the market in the form of 333mg delayed-release tablets distributed under various brand names that include Campral 333mg time-release tablets. 333mg dose of acamprosate calcium equals 300mg of acamprosate (active ingredient). Inactive ingredients in Campral tablets include: crospovidone, microcrystalline cellulose, magnesium silicate, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate, talc, propylene glycol and Eudragit L 30 D or equivalent.

Campral (acamprosate calcium) 333mg enteric-coated tablets are white-colored, round, biconvex, with "333" index debossed on one side.

Reducing distress and discomfort during abstinence, Campral 333mg tablets are used to help patients with alcohol dependence stay alcohol-free after they have stopped drinking and gone through detoxification.

In the US, Campral 333mg tablets were approved for the treatment of alcohol dependence by FDA in July 2004. However, the usage of the medication started much earlier, as it has been known in Europe since 1989.

In the US and Puerto Rico, Campral 333mg tablets are manufactured and marketed by Forest Pharmaceuticals, Inc (FPI) which is a wholly-owned subsidiary of Forest Laboratories, Inc. In Europe, the medication is distributed mainly by Merck KGaA and her subsidiaries.

Campral 333mg is a recommended initial dose of the medication which is taken three times a day. If needed, the dosage can be increased up to 666mg of Campral (i.e. two 333mg tablets) taken thrice daily.